Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Study Identifier:
13-601
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Cerdulatinib
- Biological: Rituximab
Date
Aug 2013 - Dec 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Cerdulatinib
- Biological: Rituximab
Date
Aug 2013 - Dec 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin lymphoma.
Trial Locations
Location
Status
Location
Huntsville, Alabama, United States, 35805
Status
N/A
Location
Gilbert, Arizona, United States, 85234
Status
N/A
Location
Los Angeles, California, United States, 90095
Status
N/A
Location
Palo Alto, California, United States, 94304
Status
N/A
Location
Washington, District of Columbia, United States, 20007
Status
N/A
Location
Gainesville, Florida, United States, 32608
Status
N/A